Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 after radiotherapy for newly diagnosed H3 K27M-mutant diffuse glioma
MOH_2023-01-15_012283Phase 3Recruiting
- Sponsor
- Chimerix Inc.
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diffuse midline glioma (DMG) comparing Dordaviprone twice weekly, Dordaviprone once weekly plus placebo and Placebo (3 arms). Started Dec 2022; status: recruiting.
02
Drugs
dordaviprone
03
Conditions
diffuse midline glioma (DMG)
Beyond the preview
Go deeper on MOH_2023-01-15_012283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-01-15_012283.